Jupiter Neurosciences (JUNS) Profit After Tax (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Profit After Tax of -$2.6 million for Q4 2025, down 68.56% year-over-year from -$8.2 million in Q4 2024, and down 12.54% quarter-over-quarter from -$2.3 million in Q3 2025.
Jupiter Neurosciences (JUNS) Profit After Tax (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Profit After Tax for 3 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax fell 68.56% year-over-year to -$2.6 million; the TTM figure through Dec 2025 stood at -$8.6 million (down 254.35% YoY), while the FY2025 annual figure was -$8.6 million, down 254.35% from the prior year.
- Profit After Tax fell to -$2.6 million in Q4 2025 per JUNS's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at $313123.0 in Q2 2024 and bottomed at -$2.6 million in Q4 2025.
- Historically, Profit After Tax has averaged -$1.3 million across 3 years, with a median of -$1.5 million in 2024.
- Annual changes were most pronounced in 2024 — Profit After Tax soared 66.69% — and 2025, when it tumbled 819.51%.
- Jupiter Neurosciences' Profit After Tax stood at -$429645.0 in 2023, then sank by 255.56% to -$1.5 million in 2024, then slumped by 68.56% to -$2.6 million in 2025.
- Business Quant data shows JUNS's Profit After Tax at -$2.6 million in Q4 2025, -$2.3 million in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | -2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.58 Mn |
| Sep 30, 2025 | -2.29 Mn |
| Jun 30, 2025 | -2.25 Mn |
| Mar 31, 2025 | -1.53 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -591,021.00 |
| Jun 30, 2024 | 313,123.00 |
| Mar 31, 2024 | -634,100.00 |
| Dec 31, 2023 | -429,645.00 |
| Sep 30, 2023 | -1.77 Mn |